Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beamion BCGC-1 of zongertinib in advanced HER2-positive metastatic solid tumors
CTR20242277Phase 2Active
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of zongertinib in breast cancer, gastric cancer (GC), gastroesophageal junction adenocarcinoma and 2 more, sponsored by Boehringer Ingelheim. Primary endpoints: Dose-limiting toxicity rate during MTD evaluation period and Objective response. Started Oct 2024; status: active.
02
Drugs
zongertinib
03
Conditions
breast cancergastric cancer (GC)gastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20242277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242277.